Stock NOVO B NOVO NORDISK A/S
Add to a list
To use this feature you must be a member
Log inSign up

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 11:20:00 2024-12-09 am EST 		5-day change 1st Jan Change
782.30 DKK -0.41% Intraday chart for Novo Nordisk A/S +0.84% +12.06%
Dec. 09 NOVO NORDISK : UBS reaffirms its Neutral rating ZD
Dec. 09 NOVO NORDISK : Bernstein reiterates its Sell rating ZD
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Novo Nordisk A/S

NOVO NORDISK : UBS reaffirms its Neutral rating Dec. 09 ZD
NOVO NORDISK : Bernstein reiterates its Sell rating Dec. 09 ZD
Cliens Sweden down 1.1% in November - increases exposure to Alfa Laval Dec. 09 FW
Novo Nordisk: Brussels gives the go-ahead for an acquisition Dec. 09 CF
EU approves Novo Holding's acquisition of Catalent, and Novo Nordisk's purchase of manufacturing facilities Dec. 09 FW
Carnegie raises target price for Novo Nordisk to DKK 1,090 (1,029), reiterates Buy - BN Dec. 09 FW
Novo Holdings Bags EU Approval for Catalent Acquisition Dec. 08 MT
Novo, Catalent's $16.5 Billion Deal for Weight-Loss Drug Production Gets European Commission Approval Dec. 06 DJ
Catalent's Proposed Acquisition by Novo Holdings Wins European Commission Nod Dec. 06 MT
Novo Holdings' $16.5 billion Catalent buy wins EU antitrust approval Dec. 06 RE
European Equities Traded in the US as American Depositary Tread Water in Friday Trading Dec. 06 MT
NOVO NORDISK : Interesting equations developing for Novo Nordisk Dec. 06Alphavalue
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments -- Update Dec. 05 DJ
Eli Lilly to Expand Facility to Meet Demand for Diabetes, Obesity Treatments Dec. 05 DJ
Sector Update: Health Care Stocks Retreat Late Afternoon Dec. 05 MT
Sector Update: Health Care Stocks Decline Thursday Afternoon Dec. 05 MT
Novo Nordisk to Cut Prices of Insulin Products by Over 70% Dec. 05 MT
Novo Nordisk slashes list prices of two insulin products in the US Dec. 05 FW
Denmark raises 2025 GDP outlook, benefits from Novo Nordisk's growth Dec. 05 RE
Denmark raises growth forecast again - Novo Nordisk contributing factor Dec. 05 FW
Guggenheim Securities lowers target price for Novo Nordisk to DKK 900 (1,012), reiterates Buy - BN Dec. 05 FW
Health Care Flat on Biotech, Obesity-Drug Hopes -- Health Care Roundup Dec. 04 DJ
Sector Update: Health Care Stocks Edge Lower Late Afternoon Dec. 04 MT
Sector Update: Health Care Dec. 04 MT
Lilly's Zepbound Beats Wegovy in Weight-Loss Drug Trial Dec. 04 MT

Chart Novo Nordisk A/S

Chart Novo Nordisk A/S
NOVO B: Dynamic Chart

Company Profile

Logo Novo Nordisk A/S
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Employees
71,880
Sector
Pharmaceuticals
Calendar
2025-02-05 - Q4 2024 Earnings Release
More about the company

Income Statement and Estimates

income-statement-evolution-chart NOVO-NORDISK-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart NOVO-NORDISK-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
782.30DKK
Average target price
938.17DKK
Spread / Average Target
+19.93%
Consensus
Profit revisions
estimates-change-chart NOVO-NORDISK-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart NOVO-NORDISK-A-S Company calendar
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. Sector Update: Health Care